Understanding SARS-CoV-2-Mediated Inflammatory Responses: From

Currently there is no effective antiviral therapy for SARS-CoV-2 infection, which frequently leads to fatal inflammatory responses and acute lung injury. Here, we discuss the various mechanisms of SARS-CoV-mediated inflammation. We also assume that SARS-CoV-2 likely shares similar inflammatory responses. Potential therapeutic tools to reduce SARS-CoV-2-induced inflammatory responses include various methods to block FcR activation. In the absence of a proven clinical FcR blocker, the use of intravenous immunoglobulin to block FcR activation may be a viable option for the urgent treatment of pulmonary inflammation to prevent severe lung injury. Such treatment may also be combined with systemic anti-inflammatory drugs or corticosteroids. However, these strategies, as proposed here, remain to be clinically tested for effectiveness.

Study reveals how young children's immune systems tame SARS-CoV-2

Why does COVID-19 disproportionately affect older people?

Pathogenesis of COVID-19-induced ARDS: implications for an ageing population

Full article: Short- and potential long-term adverse health outcomes of COVID-19: a rapid review

Tobacco product use and the risks of SARS-CoV-2 infection and COVID-19: current understanding and recommendations for future research - The Lancet Respiratory Medicine

Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19 - ScienceDirect

COVID-19 - Wikipedia

Associations between Children's Exposure to PM2.5 and their Serum Inflammatory Responses in Taiwan - Aerosol and Air Quality Research

Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through Analysis of Viral Genomics and Structure

JCI - SARS–CoV-2–specific T cell responses and correlations with COVID-19 patient predisposition

COVID-19 therapeutics: Challenges and directions for the future